Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
RHHBY

Roche

$30.34

0.08 (0.26%)

09:55
12/13/17
12/13
09:55
12/13/17
09:55
Conference/Events
Roche to hold a conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 23

    Dec

  • 23

    Feb

RHHBY

Roche

$30.34

0.08 (0.26%)

04:55
12/13/17
12/13
04:55
12/13/17
04:55
Conference/Events
Roche to hold a conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 23

    Dec

  • 23

    Feb

Tuesday
VRTX

Vertex

$140.91

-0.77 (-0.54%)

17:38
12/12/17
12/12
17:38
12/12/17
17:38
Initiation
Vertex initiated at Deutsche Bank »

Vertex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

16:00
12/12/17
12/12
16:00
12/12/17
16:00
Hot Stocks
Amgen raises quarterly dividend 15% to $1.32 per share »

Amgen announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 03

    Feb

  • 25

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

RHHBY

Roche

$30.26

0.04 (0.13%)

14:39
12/12/17
12/12
14:39
12/12/17
14:39
Conference/Events
Roche to hold a conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Dec

  • 23

    Feb

VRTX

Vertex

$141.68

-1.93 (-1.34%)

, PTI

Proteostasis

$2.35

-0.06 (-2.49%)

09:37
12/12/17
12/12
09:37
12/12/17
09:37
Recommendations
Vertex, Proteostasis analyst commentary at JMP Securities »

Proteostasis data not as…

VRTX

Vertex

$141.68

-1.93 (-1.34%)

PTI

Proteostasis

$2.35

-0.06 (-2.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$141.68

-1.93 (-1.34%)

, CRSP

Crispr Therapeutics

$18.41

-0.47 (-2.49%)

08:33
12/12/17
12/12
08:33
12/12/17
08:33
Hot Stocks
Vertex, Crispr Therapeutics to co-develop, co-commercialize CTX001 »

Vertex Pharmaceuticals…

VRTX

Vertex

$141.68

-1.93 (-1.34%)

CRSP

Crispr Therapeutics

$18.41

-0.47 (-2.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTI

Proteostasis

$2.35

-0.06 (-2.49%)

, VRTX

Vertex

$141.68

-1.93 (-1.34%)

07:44
12/12/17
12/12
07:44
12/12/17
07:44
Recommendations
Proteostasis, Vertex analyst commentary at Baird »

Proteostasis price target…

PTI

Proteostasis

$2.35

-0.06 (-2.49%)

VRTX

Vertex

$141.68

-1.93 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$30.26

0.04 (0.13%)

, ABBV

AbbVie

$96.47

0.52 (0.54%)

07:37
12/12/17
12/12
07:37
12/12/17
07:37
Hot Stocks
Genentech says Venclexta, Rituxan reduces risk of disease progression or death »

Genentech, a member of…

RHHBY

Roche

$30.26

0.04 (0.13%)

ABBV

AbbVie

$96.47

0.52 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Dec

  • 23

    Feb

ABBV

AbbVie

$96.47

0.52 (0.54%)

, RHHBY

Roche

$30.26

0.04 (0.13%)

07:33
12/12/17
12/12
07:33
12/12/17
07:33
Hot Stocks
AbbVie: Phase 3 study of VENCLEXTA/ VENCLYXTO meets primary endpoint »

AbbVie (ABBV) announced…

ABBV

AbbVie

$96.47

0.52 (0.54%)

RHHBY

Roche

$30.26

0.04 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Dec

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.